(TOI) Oncology Institute - Ratings and Ratios
Physician Services, Infusion, Dispensary, Clinical Trials, Radiation
TOI EPS (Earnings per Share)
TOI Revenue
Description: TOI Oncology Institute
The Oncology Institute, Inc. (TOI) is a US-based oncology company providing comprehensive medical oncology services across the country. Its business is diversified into three segments: Dispensary, Patient Services, and Clinical Trials & Other, catering to adult and senior cancer patients. The companys service portfolio includes physician services, infusion and dispensary, clinical trials, radiation, and patient support services, along with educational programs and counseling.
From a business perspective, TOIs revenue streams are likely driven by its patient services, clinical trials management, and dispensary operations. Key performance indicators (KPIs) to watch include patient volume growth, revenue per patient, and clinical trials revenue as a percentage of total revenue. Additionally, metrics such as patient retention rates, customer satisfaction scores, and the number of clinical trials managed could provide insights into the companys operational efficiency and competitiveness.
TOIs growth prospects are tied to the increasing demand for oncology services, driven by the rising incidence of cancer in the US. The companys ability to expand its patient base, enhance its service offerings, and increase its clinical trials management business will be crucial to its future success. Key metrics to monitor include same-store growth, new patient acquisition rates, and the expansion of its clinical trials portfolio.
From a financial perspective, TOIs market capitalization stands at $235.30M, indicating a relatively small-cap stock. The absence of a P/E ratio suggests that the company is currently loss-making, which is not uncommon for growth-stage companies in the healthcare sector. Return on Equity (RoE) is significantly negative, indicating substantial losses relative to shareholder equity. Investors should closely monitor the companys cash burn rate, loss per share, and progress toward profitability.
TOI Stock Overview
| Market Cap in USD | 293m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-11-15 |
TOI Stock Ratings
| Growth Rating | 10.2% |
| Fundamental | 33.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 804% |
| Analyst Rating | 5.0 of 5 |
TOI Dividends
Currently no dividends paidTOI Growth Ratios
| Growth Correlation 3m | 36.5% |
| Growth Correlation 12m | 91.6% |
| Growth Correlation 5y | -78.3% |
| CAGR 5y | -8.94% |
| CAGR/Max DD 3y | -0.09 |
| CAGR/Mean DD 3y | -0.12 |
| Sharpe Ratio 12m | -0.03 |
| Alpha | 0.16 |
| Beta | 0.767 |
| Volatility | 79.45% |
| Current Volume | 1478.3k |
| Average Volume 20d | 1302.8k |
| Stop Loss | 3 (-7.4%) |
| Signal | 0.68 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-65.9m TTM) > 0 and > 6% of Revenue (6% = 25.5m TTM) |
| FCFTA -0.19 (>2.0%) and ΔFCFTA 3.78pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.43% (prev 22.46%; Δ -13.03pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.06 (>3.0%) and CFO -10.2m > Net Income -65.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (932.0m) change vs 12m ago 1147 % (target <= -2.0% for YES) |
| Gross Margin 14.60% (prev 15.33%; Δ -0.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 250.1% (prev 201.0%; Δ 49.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.09 (EBITDA TTM -48.3m / Interest Expense TTM 10.8m) >= 6 (WARN >= 3) |
Altman Z'' -7.13
| (A) 0.25 = (Total Current Assets 104.8m - Total Current Liabilities 64.8m) / Total Assets 159.8m |
| (B) -1.55 = Retained Earnings (Balance) -247.4m / Total Assets 159.8m |
| warn (B) unusual magnitude: -1.55 — check mapping/units |
| (C) -0.33 = EBIT TTM -55.2m / Avg Total Assets 169.7m |
| (D) -1.47 = Book Value of Equity -247.4m / Total Liabilities 168.8m |
| Total Rating: -7.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.85
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -8.81% = -4.40 |
| 3. FCF Margin -7.15% = -2.68 |
| 4. Debt/Equity 22.84 = -2.50 |
| 5. Debt/Ebitda -1.70 = -2.50 |
| 6. ROIC - WACC (= -70.60)% = -12.50 |
| 7. RoE data missing |
| 8. Rev. Trend 98.25% = 7.37 |
| 9. EPS Trend 71.19% = 3.56 |
What is the price of TOI shares?
Over the past week, the price has changed by +2.21%, over one month by -19.80%, over three months by +36.13% and over the past year by +980.00%.
Is Oncology Institute a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TOI is around 3.03 USD . This means that TOI is currently overvalued and has a potential downside of -6.48%.
Is TOI a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TOI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7 | 116% |
| Analysts Target Price | 7 | 116% |
| ValueRay Target Price | 3.3 | 3.1% |
Last update: 2025-09-12 04:46
TOI Fundamental Data Overview
CCE Cash And Equivalents = 30.3m USD (Cash And Short Term Investments, last quarter)
P/S = 0.6896
P/B = 0.7617
Beta = 0.127
Revenue TTM = 424.4m USD
EBIT TTM = -55.2m USD
EBITDA TTM = -48.3m USD
Long Term Debt = 75.0m USD (from longTermDebt, last quarter)
Short Term Debt = 6.95m USD (from shortTermDebt, last quarter)
Debt = 82.0m USD (Calculated: Short Term 6.95m + Long Term 75.0m)
Net Debt = 72.9m USD (from netDebt column, last quarter)
Enterprise Value = 344.4m USD (292.7m + Debt 82.0m - CCE 30.3m)
Interest Coverage Ratio = -5.09 (Ebit TTM -55.2m / Interest Expense TTM 10.8m)
FCF Yield = -8.81% (FCF TTM -30.3m / Enterprise Value 344.4m)
FCF Margin = -7.15% (FCF TTM -30.3m / Revenue TTM 424.4m)
Net Margin = -15.53% (Net Income TTM -65.9m / Revenue TTM 424.4m)
Gross Margin = 14.60% ((Revenue TTM 424.4m - Cost of Revenue TTM 362.4m) / Revenue TTM)
Tobins Q-Ratio = -1.39 (set to none) (Enterprise Value 344.4m / Book Value Of Equity -247.4m)
Interest Expense / Debt = 2.28% (Interest Expense 1.87m / Debt 82.0m)
Taxrate = 21.0% (US default)
NOPAT = -55.2m (EBIT -55.2m, no tax applied on loss)
Current Ratio = 1.62 (Total Current Assets 104.8m / Total Current Liabilities 64.8m)
Debt / Equity = 22.84 (Debt 82.0m / last Fiscal Year total Stockholder Equity 3.59m)
Debt / EBITDA = -1.70 (Net Debt 72.9m / EBITDA -48.3m)
Debt / FCF = -2.70 (Debt 82.0m / FCF TTM -30.3m)
Total Stockholder Equity = 3.79m (last 4 quarters mean)
RoA = -41.23% (Net Income -65.9m, Total Assets 159.8m )
RoE = -1739 % (set to none) (Net Income TTM -65.9m / Total Stockholder Equity 3.79m)
RoCE = -70.02% (Ebit -55.2m / (Equity 3.79m + L.T.Debt 75.0m))
RoIC = -63.30% (NOPAT -55.2m / Invested Capital 87.2m)
WACC = 7.30% (E(292.7m)/V(374.6m) * Re(8.84%)) + (D(82.0m)/V(374.6m) * Rd(2.28%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 38.17 | Cagr: 25.07%
Discount Rate = 8.84% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -30.3m)
EPS Correlation: 71.19 | EPS CAGR: 28.68% | SUE: -0.71 | # QB: 0
Revenue Correlation: 98.25 | Revenue CAGR: 24.92% | SUE: -0.06 | # QB: 0
Additional Sources for TOI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle